Background: In response to the challenges of assessing fetal growth in obese women, guidelines recommend routine third trimester ultrasound scans.

Aim: The aim of this study was to assess the diagnostic performance of this routine scan in obese women (body mass index (BMI) ≥ 35 kg/m ).

Methods: A retrospective cohort study of 1008 pregnancies with maternal BMI ≥ 35 kg/m born after 37 weeks gestation at a Victorian hospital from 2015 to 2017. Multiple pregnancies and those affected by diabetes were excluded. Growth ultrasounds were performed between 34 + 0 and 36 + 6 weeks gestation. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the detection of large for gestational age (LGA > 90%) and small for gestational age (SGA < 10%) were calculated using ultrasound estimated fetal weight (EFW) or abdominal circumference (AC) and compared with gestational age and gender-based birthweight percentiles.

Results: Using EFW, sensitivity for detecting SGA at birth was 8.1% (six of 74) with a PPV of 100%. Sensitivity for detecting LGA at birth was 61.0% (119 of 195), PPV 54.8%. Sensitivity, specificity, PPV and NPV percentages were all lower using AC. Only 40% of actual birthweight percentiles (405/1008) were within ±10 percentiles of their growth ultrasound EFW percentile.

Conclusion: The performance of a routine third trimester ultrasound in women with BMI ≥ 35 kg/m suggests limited utility in helping identify aberrant fetal growth. This has important implications for the management of obese pregnant women.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajo.13256DOI Listing

Publication Analysis

Top Keywords

routine third
8
third trimester
8
fetal growth
8
retrospective cohort
8
cohort study
8
obese women
8
gestational age
8
growth
4
trimester growth
4
growth ultrasound
4

Similar Publications

Background: The minimally invasive repair of pectus excavatum (PE), introduced by Nuss in 1998, represents the worldwide "gold standard" procedure for surgical repair. Modifications over years included routine use of unilateral or bilateral thoracoscopy as well as sternal elevation before starting the substernal dissection. In patients with a severe PE deformity, such as Grand Canyon type, use of a second bar or, in selected patients, even a third or fourth bar has to be considered.

View Article and Find Full Text PDF

Variations in Perioperative Thromboprophylaxis Practices: Do the Guidelines Need a Closer Look?

Ann Thorac Surg Short Rep

September 2024

Division of Thoracic Surgery, Department of Surgery, Hackensack Meridian Health Network, Hackensack, New Jersey.

Background: In 2022, the American Association for Thoracic Surgery (AATS) and the European Society of Thoracic Surgeons (ESTS) published joint guidelines regarding the timing, duration, and choice of agent for perioperative venous thromboembolism prophylaxis for thoracic cancer patients. Now, 1 year after their release, we looked to assess practices and general adherence to these recommendations.

Methods: We conducted a survey among board-certified/board-eligible thoracic surgeons in the United States, between July and October 2023.

View Article and Find Full Text PDF

Background: Heart failure (HF) guidelines recommend routine testing for iron deficiency (ID) and, for those with ID, intravenous iron if the left ventricular ejection fraction is <50%. Guideline adherence to these recommendations by cardiologists in China is unknown.

Methods And Results: An independent academic web-based survey was designed and distributed via social networks to cardiologists across China.

View Article and Find Full Text PDF

Purpose: To study the application of radiomics in cancer imaging with a focus on lung cancer, renal cell carcinoma, gastrointestinal cancer, and head and neck cancer.

Methods: Different electronic databases were considered. Articles published in the last five years were analyzed (January 2019 and December 2023).

View Article and Find Full Text PDF

Importance: Bietti crystalline dystrophy (BCD) is a severe genetic retinopathy caused by variants in the CYP4V2 gene. Currently, there is no approved treatment for BCD.

Objective: To evaluate safety and vision outcomes following gene therapy with adeno-associated virus (AAV) encoding CYP4V2 (rAAV-hCYP4V2, NGGT001 [Next Generation Gene Therapeutics]).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!